This is a multi-center, observational study aiming to establish a precision diagnosis scheme and multi-dimensional risk prediction models for Hypertrophic Cardiomyopathy (HCM). The study plans to enroll 10000 adult HCM patients. It will integrate genetic testing, advanced cardiac imaging (echocardiography and cardiac magnetic resonance), and biomarker analysis to develop early diagnosis, differential diagnosis, and new risk prediction models for sudden cardiac death (SCD) and heart failure in HCM patients. Participants will undergo baseline assessments and be followed up every six months for up to 3 years to track clinical outcomes. This study is non-interventional and does not involve any investigational drugs or devices.

Inclusion Criteria:

A maximal left ventricular wall thickness of ≥ 12 mm in any segment at end-diastole, as measured by echocardiography or Cardiac Magnetic Resonance (CMR)

Exclusion Criteria:

• Presence of any contraindication to CMR examination.
• Unwillingness to participate in the study or to provide informed consent.

patients with hypertrophic myocardium experienced CMR scanning